Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
42 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Polyphor Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Polyphor Ltd. - Product Pipeline Review - 2014', provides an overview of the Polyphor Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Polyphor Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Polyphor Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Polyphor Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Polyphor Ltd.'s pipeline products Reasons to buy - Evaluate Polyphor Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Polyphor Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Polyphor Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Polyphor Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Polyphor Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Polyphor Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Polyphor Ltd. Snapshot 5 Polyphor Ltd. Overview 5 Key Information 5 Key Facts 5 Polyphor Ltd. - Research and Development Overview 6 Key Therapeutic Areas 6 Polyphor Ltd. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Polyphor Ltd. - Pipeline Products Glance 15 Polyphor Ltd. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Polyphor Ltd. - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Discovery Products/Combination Treatment Modalities 18 Polyphor Ltd. - Drug Profiles 19 POL-6326 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 POL-5551 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 POL-6014 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 POL-6926 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 POL-7080 Follow-On 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 POL-7085 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecule for Undisclosed Indication 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 PEM Candidates 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecules for Infectious Diseases 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Synthetic Peptide to Agonize FPR1/2 for Infectious Disease and Immunology 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Synthetic Peptide to Antagonize FPR1/2 for Infectious Disease and Immunology 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Synthetic Peptides to Inhibit Proteases for Respiratory and Cardiovascular Diseases 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Polyphor Ltd. - Pipeline Analysis 34 Polyphor Ltd. - Pipeline Products by Target 34 Polyphor Ltd. - Pipeline Products by Route of Administration 35 Polyphor Ltd. - Pipeline Products by Molecule Type 36 Polyphor Ltd. - Pipeline Products by Mechanism of Action 37 Polyphor Ltd. - Recent Pipeline Updates 38 Polyphor Ltd. - Dormant Projects 39 Polyphor Ltd. - Locations And Subsidiaries 40 Head Office 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 42 Disclaimer 42
List of Tables Polyphor Ltd., Key Information 5 Polyphor Ltd., Key Facts 5 Polyphor Ltd. - Pipeline by Indication, 2014 8 Polyphor Ltd. - Pipeline by Stage of Development, 2014 9 Polyphor Ltd. - Monotherapy Products in Pipeline, 2014 10 Polyphor Ltd. - Partnered Products in Pipeline, 2014 11 Polyphor Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 12 Polyphor Ltd. - Out-Licensed Products in Pipeline, 2014 13 Polyphor Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14 Polyphor Ltd. - Phase II, 2014 15 Polyphor Ltd. - Phase I, 2014 16 Polyphor Ltd. - Preclinical, 2014 17 Polyphor Ltd. - Discovery, 2014 18 Polyphor Ltd. - Pipeline by Target, 2014 34 Polyphor Ltd. - Pipeline by Route of Administration, 2014 35 Polyphor Ltd. - Pipeline by Molecule Type, 2014 36 Polyphor Ltd. - Pipeline Products by Mechanism of Action, 2014 37 Polyphor Ltd. - Recent Pipeline Updates, 2014 38 Polyphor Ltd. - Dormant Developmental Projects,2014 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.